Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of KPL-404 in Moderate to Severe Rheumatoid Arthritis
2022-000169-42Phase 2Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing KPL-404 subcutaneous with Placebo subcutaneous (2 arms). Primary endpoints: Safety and tolerability of multiple subcutaneous doses of KPL-404 (Cohorts 1 and 2) and Pharmacokinetics of multiple subcutaneous doses of KPL-404 (Cohorts 1 and 2). Started Apr 2022; status: completed.
02
Drugs
Abiprubart
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-000169-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000169-42.